Simpler antiviral treatment for HIV-hepatitis B co-infection
Treatments studied
Part of Immune system & allergy, Infections clinical trials.
This study tests whether people with both HIV and hepatitis B (HBV) can safely stop or switch parts of their antiviral treatment. It aims to see if simpler treatment can keep both viruses under control for 96 weeks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have both HIV and hepatitis B (HBsAg positive for more than 6 months).
- You have been taking a stable HIV medication combo (including tenofovir and lamivudine/emtricitabine) for at least 12 months.
- Your HIV and hepatitis B virus levels have been undetectable for at least 2 years, with only one small occasional blip allowed.
- Your liver is healthy (no significant scarring — FibroScan under 9 kPa).
- You are not pregnant, breastfeeding, and willing to use contraception if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people who have both HIV and hepatitis B over time to better understand how the infection responds after starting treatment. Your information (and sometimes stored blood samples) helps researchers track changes from the start of therapy to about 2 years later.
This study tests whether switching to a simpler, two-drug HIV pill (dolutegravir/lamivudine) is as safe and effective as staying on a three-drug regimen. It is for people whose HIV is already well-controlled and who are currently taking Biktarvy or Triumeq.
This trial studies whether taking dolutegravir plus lamivudine (a simpler two-drug regimen) can work as well as a standard three-drug HIV regimen for people who have reasons they can’t stay on the usual medicines. You may be offered free treatment if you meet the safety checks and can attend follow-up visits.
This study looks at how to best use existing hepatitis B “nucleotide-analog” tablets in everyday care. It may help tailor when to start, and whether to continue or adjust treatment, based on your test results.
This study tests if a two-drug HIV regimen (darunavir/cobicistat plus lamivudine) works as well as a standard three-drug regimen in men whose HIV is already well-controlled. If effective, this could mean taking fewer medications.
This study tests a newer HIV medication, B/F/TAF, as a first-line treatment. It compares B/F/TAF with older combinations (TDF+3TC+EFV or DTG/3TC) to see how well it works for people who have never taken HIV meds.
Hear when a new HIV Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.